Law360, New York (September 25, 2008) -- A federal judge has kept alive Shire LLC's patent infringement allegations against Sandoz Inc. over attention-deficit hyperactivity disorder drug Adderall XR, finding that questions still remain about whether Sandoz's proposed generic falls within the claims of Shire's patents.
In a ruling issued Wednesday, Chief Judge Edward W. Nottingham of the U.S. District Court for the District of Colorado denied Sandoz's bid for summary judgment of noninfringement and tossed...
